GlaxoSmithKline says five late-stage trials meet main goal
(Reuters) - GlaxoSmithKline Plc said results from five late-stage trials of two experimental quadrivalent influenza vaccines (QIV) met the main goal of protecting against mild as well as moderate-severe cases of influenza.
GSK said its experimental vaccines contain two influenza A strains and two influenza B strains to potentially help broaden protection against seasonal influenza, compared to approved trivalent vaccines that contain two A influenza strains and one B influenza strain.
(Reporting by Monika Shinghal in Bangalore)
- Tweet this
- Share this
- Digg this
- Deadly gun attack in eastern Ukraine shakes fragile Geneva accord |
- South Korea recovers first bodies from inside sunken ferry |
- Bankrupt British loans official resigns, embarrassing PM Cameron
- Special Report - How the U.S. made its Putin problem worse
- Australia sees 'regroup' on Malaysian plane search in a few days |